Skip to main content
TipRanks
Go Ultimate75% OFF

Aethlon Medical (0A6R) Share Price & Analysis

0 Followers

0A6R Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
EUR 7.09M
Enterprise Value
EUR 300.27K
Total Cash (Recent Filing)
EUR 6.49M
Total Debt (Recent Filing)
EUR 172.12K
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
Feb 15, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Progress

Advancement into the final oncology cohort and repeatable directional biomarker changes provide important clinical-development progress. While not proof of efficacy, persistence across follow-up supports continued evaluation of the Hemopurifier and could strengthen future regulatory and partnering discussions.

Platform Expansion

Expansion across multiple disease areas increases the potential addressable use cases for the Hemopurifier rather than relying on a single indication. Continued preclinical work, mechanism-focused findings and intellectual-property development can support longer-term partnering and clinical optionality.

Runway And Cost Control

Recent financing combined with lower operating expenses gives Aethlon additional time to complete its current clinical work and analyze results. Extending runway while reducing spending can improve execution discipline, although the company remains dependent on future capital for larger development programs.

Bears Say

Persistent Operating Losses

The absence of meaningful recent revenue and persistent operating losses show that the business has not yet reached commercial self-sufficiency. Continued negative cash generation limits internal funding capacity and makes progress dependent on financing, partnerships or eventual successful commercialization.

Clinical Uncertainty

Small cohorts and pending statistical analysis substantially limit confidence in the reproducibility, efficacy and generalizability of the biomarker findings. Until larger studies establish clinical benefit, the Hemopurifier remains exposed to validation risk and may face difficulty securing broad regulatory or commercial support.

Merger Dilution And Transition

The proposed transaction materially changes Aethlon investors' economic exposure and strategic direction, with North Immunology shareholders expected to own most of the combined company. Winding down certain legacy activities could also reduce the direct future influence and upside of the Hemopurifier program.

Aethlon Medical News

0A6R FAQ

What is Aethlon Medical’s market cap?
Aethlon Medical’s market cap is €7.09M.
When is Aethlon Medical’s upcoming earnings report date?
Aethlon Medical’s next earnings report is estimated for Feb 15, 2027 (not yet confirmed), which is in 85 days.
How were Aethlon Medical’s earnings last quarter?
Aethlon Medical released its earnings results on Nov 12, 2026. The company reported -€2.365 earnings per share for the quarter, beating the consensus estimate of -€2.456 by €0.091.
Is Aethlon Medical overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Aethlon Medical pay dividends?
Aethlon Medical does not currently pay dividends.
What is Aethlon Medical’s EPS estimate?
Aethlon Medical’s EPS estimate is -1.55.
What happened to Aethlon Medical’s price movement after its last earnings report?
Aethlon Medical reported an EPS of -€2.365 in its last earnings report, beating expectations of -€2.456. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Aethlon Medical?
Currently, no hedge funds are holding shares in GB:0A6R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology